The use of aminopenicillins in animals within the EU, emergence of resistance in bacteria of animal and human origin and its possible impact on animal and human health.

Aminopenicillins have been widely used for decades for the treatment of various infections in animals and humans in European countries. Following this extensive use, acquired resistance has emerged among human and animal pathogens and commensal bacteria. Aminopenicillins are important first-line treatment options in both humans and animals, but are also among limited therapies for infections with enterococci and Listeria spp. in humans in some settings. Therefore, there is a need to assess the impact of the use of these antimicrobials in animals on public and animal health. The most important mechanisms of resistance to aminopenicillins are the ß-lactamase enzymes. Similar resistance genes have been detected in bacteria of human and animal origin, and molecular studies suggest that transmission of resistant bacteria or resistance genes occurs between animals and humans. Due to the complexity of epidemiology and the near ubiquity of many aminopenicillin resistance determinants, the direction of transfer is difficult to ascertain, except for major zoonotic pathogens. It is therefore challenging to estimate to what extent the use of aminopenicillins in animals could create negative health consequences to humans at the population level. Based on the extent of use of aminopenicillins in humans, it seems probable that the major resistance selection pressure in human pathogens in European countries is due to human consumption. It is evident that veterinary use of these antimicrobials increases the selection pressure towards resistance in animals and loss of efficacy will at minimum jeopardize animal health and welfare.

The use of aminoglycosides in animals within the EU: development of resistance in animals and possible impact on human and animal health: a review.

Aminoglycosides (AGs) are important antibacterial agents for the treatment of various infections in humans and animals. Following extensive use of AGs in humans, food-producing animals and companion animals, acquired resistance among human and animal pathogens and commensal bacteria has emerged. Acquired resistance occurs through several mechanisms, but enzymatic inactivation of AGs is the most common one. Resistance genes are often located on mobile genetic elements, facilitating their spread between different bacterial species and between animals and humans. AG resistance has been found in many different bacterial species, including those with zoonotic potential such as Salmonella spp., Campylobacter spp. and livestock-associated MRSA. The highest risk is anticipated from transfer of resistant enterococci or coliforms (Escherichia coli) since infections with these pathogens in humans would potentially be treated with AGs. There is evidence that the use of AGs in human and veterinary medicine is associated with the increased prevalence of resistance. The same resistance genes have been found in isolates from humans and animals. Evaluation of risk factors indicates that the probability of transmission of AG resistance from animals to humans through transfer of zoonotic or commensal foodborne bacteria and/or their mobile genetic elements can be regarded as high, although there are no quantitative data on the actual contribution of animals to AG resistance in human pathogens. Responsible use of AGs is of great importance in order to safeguard their clinical efficacy for human and veterinary medicine.

Public health risk of antimicrobial resistance transfer from companion animals.

Antimicrobials are important tools for the therapy of infectious bacterial diseases in companion animals. Loss of efficacy of antimicrobial substances can seriously compromise animal health and welfare. A need for the development of new antimicrobials for the therapy of multiresistant infections, particularly those caused by Gram-negative bacteria, has been acknowledged in human medicine and a future corresponding need in veterinary medicine is expected. A unique aspect related to antimicrobial resistance and risk of resistance transfer in companion animals is their close contact with humans. This creates opportunities for interspecies transmission of resistant bacteria. Yet, the current knowledge of this field is limited and no risk assessment is performed when approving new veterinary antimicrobials. The objective of this review is to summarize the current knowledge on the use and indications for antimicrobials in companion animals, drug-resistant bacteria of concern among companion animals, risk factors for colonization of companion animals with resistant bacteria and transmission of antimicrobial resistance (bacteria and/or resistance determinants) between animals and humans. The major antimicrobial resistance microbiological hazards originating from companion animals that directly or indirectly may cause adverse health effects in humans are MRSA, methicillin-resistant Staphylococcus pseudintermedius, VRE, ESBL- or carbapenemase-producing Enterobacteriaceae and Gram-negative bacteria. In the face of the previously recognized microbiological hazards, a risk assessment tool could be applied in applications for marketing authorization for medicinal products for companion animals. This would allow the approval of new veterinary medicinal antimicrobials for which risk levels are estimated as acceptable for public health.

Determination of ochratoxin A in Capsicum spp. (paprika and chili) by immunoaffinity column cleanup and liquid chromatography: collaborative study.

A method validation study for the determination of ochratoxin A in Capsicum spp. (paprika and chili) was conducted according to the International Union of Pure and Applied Chemistry harmonized protocol. The method is based on the extraction of samples with aqueous methanol, followed by an immunoaffinity column cleanup. The determination is carried out by RP-HPLC coupled with a fluorescence detector. The study involved 21 participants representing a cross-section of research, private, and official control laboratories from 14 European Union (EU) Member States and Singapore. Mean recoveries reported ranged from 83.7 to 87.5%. The RSD for repeatability (RSDr) ranged from 1.7 to 14.3%. The RSD for reproducibility (RSDR) ranged from 9.1 to 27.5%, reflecting HorRat values from 0.4 to 1.3 according to the Horwitz function modified by Thompson. The correction for recovery of results from naturally contaminated samples further improved the reproducibility of the method. The method showed acceptable within-laboratory and between-laboratory precision for each matrix, and it conforms to requirements set by current EU legislation.

Determination of ochratoxin A in licorice and licorice extracts by high-performance liquid chromatography coupled with fluorescence detection: collaborative study.

A collaborative study was conducted to validate an analytical method for the determination of ochratoxin A (OTA) in licorice (root powder) and licorice extracts (paste and powder). Contents of OTA ranged from 26 to 141 microg/kg and from 8 to 52 microg/kg for licorice extracts and root material, respectively. For the analysis, a test portion is extracted with a mixture of methanol and aqueous sodium bicarbonate solution. The extract is filtered and diluted with phosphate-buffered saline; and OTA is purified with an immunoaffinity column containing antibodies specific to OTA. The purified extract is dried, reconstituted, and quantified by HPLC with fluorescence detection. Twenty laboratories from 13 European Union member states, Uruguay, Turkey, and the United States of America participated in this study. The study was evaluated according to internationally accepted guidelines. The method performance characteristics can be summarized as follows: over a working range of 7.7 to 141 microg/kg OTA, the mean recoveries were 87% for licorice root and 84-88% for licorice extracts; and the RSDs for reproducibility ranged from 10 to 17% and from 11 to 22% in licorice extracts and licorice root, respectively. The method was found to be fit-for-purpose and to fulfill legal requirements as set in EC Regulation No. 401/2006.